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Abstract
Background: Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies and has a high
mortality rate due to late detection and lack of efficient treatments. Identifying novel drug targets for this
indication may open the way for new treatment strategies. Comparison of gene expression profiles of NSCLC and
normal adjacent tissue (NAT) allowed to determine that 5-alpha-reductase type I (SRD5A1) was up-regulated in
NSCLC compared to NAT. This raised the question whether SRD5A1 was involved in sustained proliferation and
survival of NSCLC.
Methods: siRNA-mediated silencing of SRD5A1 was performed in A549 and NCI-H460 lung cancer cell lines in
order to determine the impact on proliferation, on distribution during the different phases of the cell cycle, and on
apoptosis/necrosis. In addition, lung cancer cell lines were treated with 4-azasteroids, which specifically inhibit
SRD5A1 activity, and the effects on proliferation were measured. Statistical analyses using ANOVA and post-hoc
Tamhane-T2-test were performed. In the case of non-parametric data, the Kruskal-Wallis test and the post-hoc
Mann-Whitney-U-test were used.
Results: The knock-down of SRDA51 expression was very efficient with the SRD5A1 transcripts being reduced to
10% of control levels. Knock-down efficiency was furthermore confirmed at the protein level. However, no effect of
SRD5A1 silencing was observed in the proliferation assay, the cell cycle analysis, and the apoptosis/necrosis assay.
Treatment of lung cancer cell lines with 4-azasteroids did not significantly inhibit proliferation.
Conclusions: In summary, the results suggest that SRD5A1 is not a crucial enzyme for the sustained proliferation
of NSCLC cell lines.
Background
Lung cancer remains one of the leading causes of mor-
bidity and mortality in cancer patients, and its prognosis
is unsatisfactory with an overall survival of 15-18% [1].
Surgical resection promotes good long-term survival in
the early stages with up to 57%-71% in stage I non-
small cell lung cancer (NSCLC) [2] and 33-57% in stage
II NSCLC [3]. Unfortunately, late diagnosis is common
due to the lack of early symptoms, which explains the
low survival rates. Chemotherapy in the late stages III
and IV did improve the outcome in the last decades,
but only slightly from 10% in the 1980s to 15-18%
nowadays. Thus, new and more effective treatment stra-
tegies are urgently needed. Several genome-wide gene
expression profiling studies have been performed in the
past years (reviewed by Mueller-Hagen et al. [4]). These
analyses provide valuable diagnostic and prognostic
markers as well as a basis for the discovery of novel tar-
get candidates for the therapy of NSCLC. More recently,
a genome-wide expression profiling analysis of matching
pairs of NSCLC and normal adjacent tissue (NAT) on * Correspondence: bernard.haendler@bayer.com
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dence for genes alternatively spliced in NSCLC [5].
Two main steroid 5-alpha-reductases have been iden-
tified, 5-alpha-reductase type I (SRD5A1) and 5-alpha-
reductase type II (SRD5A2) [6]. The recently described
type III (SRD5A3) [7] was originally identified in pros-
tate cancer tissue and acts as a polyprenol reductase
involved in the N-linked glycosylation of proteins [8].
SRD5A1 is expressed mainly in the skin from the time
of puberty while SRD5A2 is the predominant enzyme in
the prostate and male accessory sex glands [9]. While
SRD5A2 is an initiating factor for male pattern baldness,
its germ line deficiency results in male pseudohermaph-
roditism, which is characterized by phenotypically
female external genitalia at birth. It has been suggested
that SRD5A1 and SRD5A2 are involved in the patho-
genesis of polycystic ovary syndrome [10]. So far, only
few publications examined ther o l eo f5 - a l p h a - r e d u c -
tases in the lung and in lung cell lines, with partly con-
flicting results. Provost et al. detected only a small
amount of SRD5A1 mRNA and only little enzymatic
activity of SRD5A1 in A549 lung cancer cells [11]. In a
microarray analysis of different tissues, SRD5A1 expres-
sion has been described as being low in normal lung tis-
sue [12]. So far, there have been no reports on the
expression level of SRD5A1 mRNA in NCI-H460 cells.
Over-expression of SRD5A1 and SRD5A2 has been
noted in breast and prostate cancer samples [13,14].
In preliminary studies with Affymetrix GeneChips,
SRD5A1 was identified as up-regulated in NSCLC com-
pared to NAT. The hypothesis was developed that
SRD5A1 was possibly involved in sustaining the prolif-
eration in NSCLC cell lines. In order to analyze this,
knock-down of SRD5A1 expression was performed and
the effects on cell growth, cell cycle distribution, apop-
tosis, and necrosis were determined. In addition, the
impact of blocking the enzymatic activity of SRD5A1
with compounds selective for SRD5A1 such as 4-azas-
teroids was studied.
Methods
Clinical samples
Lung cancer samples and NAT were obtained with
informed consent from patients treated at the Depart-
ment of General, Vascular and Thoracic Surgery and at
the Institute of Pathology, Charité, Universitätsmedizin
Berlin, Campus Benjamin Franklin, Berlin, Germany [5].
Cell lines and culture
The human NSCLC cell lines A549 and NCI-H460
(H460) were obtained from ATCC (ATCC, Manassas,
VA, USA). Both cell lines were cultured in DMEM/
Ham’s F12 medium (Biochrom AG, Berlin, Germany)
supplemented with 2 mM L-glutamine (Invitrogen,
Carlsbad, CA, USA), 100 units/ml penicillin G and 100
μg/ml streptomycin (Invitrogen). Also, fetal calf serum
(FCS; Biochrom AG), which contains 0.03 ng/ml testos-
terone, was added to a final concentration of 10%. The
cells were grown at 37.0°C, in 5% CO2 and 95% relative
humidity.
Affymetrix microarray analysis
RNA was transcribed into cRNA and hybridized onto
Affymetrix GeneChip HG-U133Plus2.0 The hybridiza-
tion intensities on each array were calculated with the
MAS5.0 summarization algorithm. The refined and
summarized data were loaded into the CoBi database
(Genedata, Basel, CH). The analysis of the probeset-spe-
cific signal intensities was performed with the Genedata
Expressionist Version 6.1 software (Genedata, Basel,
CH). The dataset was normalized using Central Ten-
dency Median Normalization. The Genedata software
was used for Principal Component Analysis (PCA) and
statistical tests. SRD5A1 expression was analyzed using
t h ei n - h o u s ea v a i l a b l eA r r a yN o r t h e r nd a t a b a s e[ 1 5 ] .
Here, the expression values for a specific gene were dis-
played as a bar graph of the geometric mean values of
the expression value on an arbitrary scale over all sam-
ples belonging to a specific class (e.g. tissue or organ
type, cell line). For a number of organs, the expression
levels in corresponding cancer samples are additionally
shown. First, the expression data were transformed into
logarithmic scale, then a calculation of the arithmetic
mean and standard deviation was performed. After-
wards, the mean values were transformed to mean +/-
standard deviation on a linear scale.
siRNA knock-down studies
Stealth™ siRNAs (Invitrogen) were used for the knock-
down experiments. In total, three different siRNAs tar-
geting SRD5A1 and three mismatch siRNAs were used
(see Table 1 for details). The siRNAs were screened for
sequence similarities with NCBI BLAST using the
“Human genomic plus transcript” database in the
nucleotide BLAST setting. All three siRNAs directed
against human SRD5A1 were 100% identical to the tran-
script of human SRD5A1 with a query coverage of 100%
and an E-value of 4 × 10
-5 (see also Additional File 1).
Few other transcripts occurred in the BLAST and they
showed only little similarity (52-60% query coverage, E-
value of 33-509) and were considered irrelevant. Mis-
match siRNAs were also blasted and showed virtually
no similarity to any transcript (52-56% query coverage,
E-value of 129-509). Unwanted off-target effects were
therefore not expected for the selected siRNAs. Results
are displayed for transcript matches only. The binding
sites of the target siRNAs (siRNA 1-3) are displayed in
Additional File 1.
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Lipofectamine™ 2000 (Invitrogen) and OPTI-MEM I
(Invitrogen) were used for the transfection of siRNA
into cultured cells. BLOCK-iT™ Fluorescent Oligo
(Invitrogen) was used to visualize successful transfection
via fluorescence microscopy. The lowest amount of
siRNA required for a consistent knock-down of
SRD5A1 was determined to be 10 pmol. For transfec-
tion, 5 μl of Lipofectamine™ 2000 were used per well of
a six-well culture plate (TPP, Trasadingen, Switzerland).
In order to reduce possible toxic effects, the amount of
Lipofectamine™ 2000 was lowered to 2.5 μlp e rw e l li n
the course of the experiments.
Expression analysis by quantitative real-time PCR (qRT-
PCR)
RNA was extracted with the RNeasy
® Mini Kit (Qiagen,
Hilden, Germany), followed by digestion of genomic
DNA using the RNase free DNase-Set (Qiagen). RNA
content was measured by spectrophotometry. The
cDNA synthesis was conducted with SuperScript™ III
First-Strand Synthesis System for RT-PCR (Invitrogen)
using 1 μg of the extracted total RNA. The cDNA was
analyzed in a multiplex analysis using TaqMan
® Univer-
sal PCR MasterMix and specific primers for SRD5A1 or
the internal controls (Applied Biosystems, Foster City,
CA, USA). The primers specific for SRD5A1 had the
Assay ID: Hs00602694_mH, reporter dye FAM). Cyclo-
philin A served as the endogenous control and had the
reference 4310883E (VIC/TAMRA Probe, Primer Lim-
ited). The reagents were assembled in MicroAmp™ Fast
Optical 96-Well Reaction Plates (Applied Biosystems)
and the PCR reaction was conducted in a 7500 Fast
Real-Time PCR System (Applied Biosystems). The regu-
lar RT-PCR program was used and the read-out was set
to automatic threshold (Ct). Each cell culture sample
was measured in triplicates, non-template controls were
included to detect potential contamination. In order to
apply the ΔΔCt method, a validation experiment accord-
ing to the protocol provided by Applied Biosystems [16]
was conducted first, to demonstrate that multiplex ana-
lysis of SRD5A1 and cyclophilin was feasible. The vali-
dation experiment was successful with an absolute value
of the slope of ΔCt vs. log input of RNA being < 0.1
(-0,07, data not shown). The qRT-PCR protocol from
Applied Biosystems [15] and the publication by Yuan et
al [17] describe the ΔΔCt-method used for analysis of
the real-time PCR data. In brief, the cycle number at the
Ct for the target gene (SRD5A1) was subtracted by the
Ct of the reference gene (cyclophilin A) to give the ΔCt
value. The ΔCt of the treated sample was then sub-
tracted from the ΔCt of the untreated sample to give
ΔΔCt. The exponential function of 2
-ΔΔCt represents the
relative amount of the target gene in the treated sample
compared to the target gene in the untreated control.
For the quantitative expression analysis of lung carci-
noma and NAT samples obtained from patients, addi-
tional SRD5A1 primers were used (Assay ID
Hs00971643_g1, reporter Dye FAM), as well as a second
internal control, namely 18S rRNA (Reference
4319413E, VIC/MGB probe, Primer Limited). RNA and
cDNA were prepared as before, and the regular RT-PCR
program used to determine Ct values. Each sample value
was obtained by the average of duplicate experiments.
The mean Ct value (raw means and standard deviation)
measured for the different primers is shown in Table 2.
For statistical analysis, the repeated measures design
(per patient: lung carcinoma and NAT, SRD5A1 and
control primer pairs) was taken into account and a
mixed linear model was used for fitting.
Table 1 Human SRD5A1 specific and mismatch (mm) siRNAs.
Abbreviation Target Name Sequence
siRNA 1 SRD5A1 NM_001047.1_STEALTH_406 CCACTACGGGCATCGGTGCTTAATT
mm 1 Mismatch NM_001047.1_STEALTH_CTL_406 CCAGGCATACGTGGCTTCGATCATT
siRNA 2 SRD5A1 NM_001047.1_STEALTH_ 542 GCAGTGTATGCTGATGACTGGGTAA
mm 2 Mismatch NM_001047.1_STEALTH_ CTL_542 GCATATGGTCGAGTAGGTCGTCTAA
siRNA 3 SRD5A1 NM_001047.1_STEALTH_701 GAATACGTAACTGCAGCCAACTATT
mm 3 Mismatch NM_001047.1_STEALTH_ CTL_701 GAAATGCGTCACGACCAACTATATT
Table 2 Expression levels of SRD5A1 in NSCLC and NAT
samples as measured by qRT-PCR.
Primer
target
Analyzed
biopsy
Number
of
samples
Average
Ct
Average
standard
deviation
SRD5A1 #1 NAT 9 30.74 0.97
tumor 23 29.25 1.37
SRD5A1 #2 NAT 9 31.30 1.16
tumor 23 29.45 1.69
Cyclophilin NAT 9 21.28 0.52
tumor 23 20.46 0.98
18S rRNA NAT 9 16.94 0.56
tumor 23 17.01 0.67
The analysis was performed on tumor samples from 23 patients, of which 9
provided NAT as well.
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The cells were suspended in M-PER buffer (Pierce Bio-
t e c h n o l o g y ,R o c k f o r d ,I L ,U S A) for protein extraction.
The protein lysate was then run on NuPAGE 12% Bis-
Tris Gel (Invitrogen) and blotted onto PVDF mem-
branes (Invitrogen). The membranes were then rinsed
with 0.1% Tween
® 20 (Carl Roth GmbH + Co. KG,
Karlsruhe, Germany) and blocked with 5% milk powder
(Carl Roth GmbH). Rabbit polyclonal anti-5-alpha-
reductase 1 H-105 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and goat anti-SRD5A1 / 5-alpha-
reductase antibodies (Everest Biotech Ltd., Upper Hey-
ford, UK) were used with the respective secondary anti-
bodies for detection of SRD5A1. Mouse anti-GAPDH
antibody (Advanced Immunochemical, Long Beach, CA,
U S A )w a su s e da sl o a d i n gc o n t r o l .T h et w oa n t i -
SRD5A1 antibodies either resulted in no bands detected
on the immunoblot or multiple non-specific bands and
could not be used for determination of SRD5A1 protein
levels after knock-down. A plasmid containing a cDNA
of the human SRD5A1 gene with a V5-epitope at the C-
terminus was therefore used to overexpress SRD5A1 in
the two lung cancer cell lines and a mouse monoclonal
anti-V5 antibody (Invitrogen) was used for detection. A
sheep ECL Anti-Mouse IgG, Horseradish Peroxidase-
Linked Antibody (Amersham Biosciences, GE Health-
care Bio-Sciences AB, Uppsala, Sweden) was used as a
secondary antibody. The immunoblot was developed
with Western Lightning Reagent (PerkinElmer Inc.,
Waltham, MA, USA) on Amersham Hyperfilm ECL (GE
Healthcare Life Sciences, Munich, Germany) in a Curix
60 device (Agfa, Mortsel, Belgium). The immunoblots
were analyzed with the ImageJ software (by Waynde
Rasband (NIH), Washington D.C., USA) according to
the protocol by Miller [18].
Plasmid transformation, purification and transfection
Due to the difficulties in quantifying the reduction of
SRD5A1 protein with commercially available SRD5A1
antibodies, an immunoblot with antibodies against the
V5 epitope was performed. The expression construct
was generated by cloning human SRD5A1 cDNA into
the pcDNA/V5-His vector (Invitrogen), for details see
Additional File 2. Plasmid transformation was conducted
with XL1-Blue Supercompetent Cells (Stratagene, Santa
Clara, CA, USA) and the heat-shock method at 42°C for
45 s. Cells were then cooled and incubated on agar
plates at 37°C overnight. Single colonies were selected
and transferred into LB-medium containing ampicillin
and shaken at 37° overnight. The cells were then centri-
fuged and processed with the QIAfilter Plasmid Kit
(QIAGEN) to extract recombinant plasmid. Purified
plasmid (0.5 μg) was then transfected into A549 and
NCI-H460 cells using 5 μl of Lipofectamine™ 2000. In
order to verify successful transfection, a GFP-containing
plasmid was transfected in a separate well and fluores-
cence microscopy was conducted the next day. After 24
h, the cells were transfected with siRNAs following the
method described above using 10 μls i R N Aa n d3 . 7 5μl
Lipofectamine™ 2000. The cells were harvested 24 h
and 48 h after siRNA transfection.
Proliferation assay
24 h, 48 h and 72 h after transfection of siRNAs, Ala-
marBlue (BioSource Europe, Nivelles, Belgium) was
added to the cultured cells which were then incubated
for 1 h 45 min before being measured in a Victor3 1420
Multilabel Counter (Perkin Elmer Inc.) (excitation 530
nm, emission 590 nm). The results were compared to
the 24 h time-point of non-treated control cells and are
displayed as percentage.
Cell cycle analysis
24 h, 48 h and 72 h after transfection with siRNAs, cells
were collected, washed twice with PBS, fixed in 70%
ethanol and frozen overnight. After thawing, RNase A
(Sigma-Aldrich, St. Louis, MO, USA) and propidium
iodide (Sigma-Aldrich) were added. Distribution in the
cell cycle was analyzed on a FACSCalibur (BD Bios-
ciences, San Jose, CA, USA) flow cytometer using the
CellQuest Pro software (BD Biosciences). A total of
10,000 cells was counted per treatment group.
Apoptosis/necrosis assay
24 h, 48 h and 72 h after transfection with siRNAs, cells
were collected and washed with PBS. The Annexin V-
FITC Apoptosis Detection Kit I (BD Biosciences) was
used for detection of apoptosis and necrosis. In brief,
the cells were washed with PBS and afterwards with
Annexin Binding Buffer. After centrifugation, the super-
natant was discarded, Binding Buffer as well as Annexin
V-FITC and propidium iodide were added to the cells
which were incubated for 15 min at room temperature
in the dark. After incubation, Binding Buffer was added
and the analyses were performed in the flow cytometer
mentioned above, with 10,000 cells being counted per
treatment group.
Chemosensitivity assay
Three 17-methylene-4-azasteroids (see Additional File 3)
inhibiting SRD5A1 selectively [19] (ZK-879, ZK-924,
ZK-425 [20]; Jenapharm GmbH, Jena, Germany) and
Finasteride (Sigma), a SRD5A2 inhibitor, were diluted in
ethanol to concentrations ranging from 10
-5 Mt o1 0
-9
M. The fully synthetic sagopilone (ZK-EPO) (Bayer
HealthCare, Berlin, Germany), a microtubule inhibitor
[21],[22] was used as positive control for proliferation
inhibition at concentrations ranging from 10
-7 Mt o1 0
-9
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e r a t i o na s s a yd e s c r i b e da b o v ea t2 4h ,7 2h ,a n d1 2 0h .
Ethanol diluted at the appropriate concentration was
used as vehicle control.
Statistical analyses of cell culture experiments
For parametrical data, a two-tailed one-factor ANOVA
was conducted, with Dunnett’s test in case of equal var-
iances and Tamhane’s T2 in case of unequal variances.
If the data were non-parametric, a Kruskal-Wallis-Test
was performed, the post-hoc analysis was done with a
Mann-Whitney-U-Test. The threshold for significant
results was p < 0.05. Significant results are indicated in
the legends of the figures. All experiments except flow
cytometry were conducted three times, each one with
three replicates. Flow cytometry analyses were con-
ducted three times, each one with one sample (10,000
analyzed cells), making the calculation of a p-value not
useful but giving reliable results based on approximately
30,000 analyzed cells.
Results
Expression analysis of SRD5A1 in lung tumor samples
and cell lines
A total of 37 patients’ samples, ten cases of adenocarci-
nomas and nine matching samples of NAT from adeno-
carcinoma (AdenoCa), eleven cases of squamous cell
carcinoma (SCC) and seven matching samples of NAT
from SCC, were obtained. RNA was isolated, labeled
and hybridized to Affymetrix HGU133Plus2.0 arrays.
The results were analyzed with the Expressionist soft-
ware. Following normalization, a PCA was performed
(Figure 1). The PCA demonstrated that all adenocarci-
noma and SCC samples clustered separately from all
NAT samples. Two different two-group tests were
applied for comparison of NSCLC and NAT, the Welsh
test and the N-fold regulation test. The identified gene
groups were merged and K-means clustering was per-
formed. Groups of up- and down-regulated genes were
identified. Several criteria such as consistency of over-
expression, tissue distribution, potential role in a disease
process, as well as druggability were then used to select
the most interesting target candidate genes for valida-
tion [15].
It was found that the expression of SRD5A1 was sig-
nificantly up-regulated in the examined NSCLC samples
compared to NAT. Comparison of the signal intensities
showed a 3.3- and 6.3-fold stronger signal of SRD5A1
mRNA in adenocarcinoma and SCC of the lung, respec-
tively, when compared to NAT (Figure 2A). For nine
cases of adenocarcinoma and seven cases of cases of
SCC, matching samples from cancer and NAT were
available. Here, a pairwise comparison of the samples is
displayed. In all paired cases, SRD5A1 was expressed at
a higher level in the cancer than in the NAT samples
(Figure 2B).
In order to further substantiate these data, clinical
samples from 23 additional lung cancer patients were
analyzed. One tumor sample was obtained from each
patient and in 9 cases an NAT sample was available as
well. Following RNA extraction and cDNA synthesis,
qRT-PCR was performed using two different primer sets
specific for SRD5A1. In parallel, the expression levels
for the housekeeping gene cyclophilin A and for 18S
rRNA were determined. Comparison of the measured Ct
values showed that for these samples also, there was a
significantly higher expression of SRD5A1 in lung
tumors than in NAT (p = 0.0007 for SRD5A1 primer
pair #1, p = 0.0011 for SRD5A1 primer pair #2; Table
2). Conversely, the levels of cyclophilin A and of 18S
rRNA did not differ significantly between both groups
(p = 0.3008 and p = 0.6570, respectively; Table 2).
F i n a l l yw ed e t e r m i n e dt h eexpression of SRD5A1 in
cell lines originating from NSCLC. Similar transcript
levels were measured in A549, NCI-H322, NCI-H460
and LXF-289 cells (Figure 2C).
Expression analysis of SRD5A1 in other tumors
The expression of SRD5A1 in additional tumors was
determined by Array Northern. Besides in NSCLC,
over-expression of SRD5A1 was observed in breast can-
cer, and also in ovary, cervix and prostate cancer. In the
Array Northern shown in Figure 3, the gene expression
values for SRD5A1-based on the Affymetrix
Figure 1 PCA allows to distinguish NSCLC from NAT. Ten cases
of adenocarcinomas (AdenoCa) and nine NAT matching samples,
and eleven cases of SCC and seven NAT matching samples were
hybridized to Affymetrix HGU133Plus2.0 arrays. All NSCLC samples
(indicated in shades of red) clustered separately from the NAT
samples (indicated in shades of green).
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of the geometric mean values of the expression value on
an arbitrary scale. The expression pattern of SRD5A1
was also analyzed in a large panel of normal human
tissues. Strong expression signals were detected in skin,
brain, liver, esophagus and small intestine (Additional
File 4A). Strong expression in the skin has previously
been noted [9,23]. Expression of SRD5A1 was also
detected in many different human cell lines on the
Array Northern (Affymetrix HGU133Plus2.0 array), with
highest levels observed in breast cancer cells (Additional
File 4B).
SRD5A1 knock-down efficiency at the mRNA level
NSCLC is the most frequent lung cancer type (approxi-
mately 80% of cases) and the focus of the present study.
SRD5A1 expression was very similar in the four NSCLC
cell lines analyzed (Figure 2C) and A549 and NCI-H460
cells were chosen for further analyses. Starting with 50
ng of cDNA for analysis with qRT-PCR, the Ct was
approximately 26 for SRD5A1 in both cell lines com-
pared to 18 for cyclophilin A, an abundant housekeep-
ing mRNA. The ΔCT value for both cell lines was
approximately 8 cycles. To establish the lowest amount
of siRNAs still inducing an effective knock-down, con-
centrations ranging from 10 pmol to 100 pmol of
siRNA per well of a six-well culture dish were used and
the knock-down was measured at 24 h, 48 h, and 72 h
post-transfection. The lowest siRNA concentration caus-
ing an efficient knock-down was used for the subse-
quent experiments in order to minimize potential off-
target effects [24],[25]. In these experiments, 10 pmol
siRNA transfected with 5 μl of Lipofectamine™ 2000
were sufficient to achieve a very effective reduction,
A 
B 
C 
Figure 2 Expression of SRD5A1 in lung tumors, NAT and lung
cell lines. (A) Three independent probesets (204675_at, 210959_at,
and 211056_at) were used to measure the SRD5A1 mRNA levels
using the HGU133Plus2.0 array. The bar chart indicates that SRD5A1
was significantly and consistently up-regulated in the NSCLC
samples compared to NAT. Comparison of the signal intensities
showed a 3.3- and 6.3-fold stronger signal of SRD5A1 mRNA in
adenocarcinoma and SCC of the lung, respectively, when compared
to NAT. The mean values with one standard deviation are depicted
on the right. (B) For eight cases of adenocarcinoma (AdenoCa) and
seven cases of SCC, matching samples from cancer and NAT were
available. Here, a pairwise comparison of the samples is displayed.
In all paired cases, SRD5A1 is expressed at a higher level in the
cancer than in the NAT samples. (C) Four NSCLC cell lines were
analyzed using the Array Northern database. The results for the
SRD5A1-specific probeset 204675_at are shown. The numbers
indicate the number of replicates analyzed. Expression levels in the
NSCLC cell lines A549 and NCI-H460 (indicated with an arrowhead),
and LXF-289 and NCI-H322 (abbreviated H-322) are shown.
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Figure 3 Expression of SRD5A1 in the female and male
reproductive tract. SRD5A1 over-expression was observed in
breast, fallopian tube, ovary, cervix and prostate cancer on the
Affymetrix HGU133Plus2.0 array with the SRD5A1-specific probeset
204675_at.
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control in both A549 and NCI-H460 cells (Additional
File 5). “siRNA 1-3” refers to the target siRNAs 1, 2 and
3 in all diagrams while “mm 1-3” refers to the mismatch
controls 1, 2 and 3. The knock-down of SRD5A1 was
stable at 48 h and 72 h in both cell lines, and higher
amounts of siRNA (50 pmol and 100 pmol) did not
further reduce SRD5A1 levels (data not shown). Due to
the toxicity observed in the proliferation assays, the
knock-down assays were conducted again with a
reduced amount of Lipofectamine™ 2000, with 2.5 μl
being used per well. The results are displayed in Figure
4. Here also, very good knock-down efficiency was
achieved and the effects were stable over 72 h (data not
shown).
SRD5A1 knock-down efficiency at the protein level
Following establishment of the knock-down conditions
at the RNA level, an immunoblot was performed to ana-
lyze the reduction of protein levels. The two anti-
SRD5A1 antibodies used did either not allow to detect
bands or showed multiple non-specific bands on the
immunoblot of A549 or NCI-H460 cells (not shown).
Similar results were obtained in cells transfected with an
SRD5A1 expression plasmid (not shown). Thus these
antibodies could not be used for evaluating the SRD5A1
protein levels after siRNA-mediated knock-down. V5-
tagged SRD5A1 protein over-expressed in A549 or NCI-
H460 was, however, detected as a specific band with an
anti-V5-antibody. This antibody was subsequently used
to analyze whether siRNAs directed against human
SRD5A1 induced knock-down of SRD5A1 at the protein
level. The results are displayed in Figure 5 for the A549
cells. They show that the SRD5A1-V5 protein levels
were decreased by 69-78% 24 h after siRNA transfection
in comparison to the mismatch controls. A reduction of
SRD5A1-V5 levels was still detected at 48 h, although
the levels of transfected SRD5A1-V5 were already
declining at this time point (data not shown). Similar
observations were made to a lesser extent in NCI-H460
cells (not shown). The results indicate that the three
siRNAs against SRD5A1 reduced the protein expression
of SRD5A1-V5 after 24 h by 69-78% in A549 and by 20-
49% in NCI-H460, suggesting a half-life of approxi-
mately 12 h in A549 cells and 20-30 h in NCI-H460
cells.
Proliferation assay
The lung cancer cell lines were grown in medium sup-
plemented with FCS, which contains 0.03 ng/ml testos-
terone. Next, A549 or NCI-H460 cells were transfected
with 10 pmol of each siRNA in presence of 2.5 μl Lipo-
fectamine™ 2000. An Alamar Blue proliferation assay
was then performed (Figure 6). In comparison to the
preceding proliferation assay with 5 μl Lipofectamine™
2000 (Additional File 6), only little toxicity was
observed. No noticeable difference was visible in the
proliferation between cells with silenced SRD5A1 and
the mismatch controls.
Cell cycle analysis
In addition to the proliferation assays, flow cytometry
was performed to analyze cell cycle distribution and
apoptosis/necrosis assays to find out whether more dis-
crete changes were noticeable after the silencing of
SRD5A1 expression. The results of the cell cycle analysis
72 h after knock-down with 2.5 μl Lipofectamine™ 2000
and 10 pmol siRNA are displayed in Figure 7. The sub-
A                                                                    A549 
B                                                                       NCI-H460 
Figure 4 Relative gene expression of SRD5A1 normalized to
cyclophilin after 24 h of siRNA treatment in A549 (A) and NCI-
H460 (B) cells. Experiments were performed in triplicate with 10
pmol siRNA and 5 μl Lipofectamine™ 2000. (A) A549: * significant
difference to untreated (siRNA 1: P = 0.001), **significantly smaller
than 5% (siRNA 2: P < 0.001, siRNA 3: P < 0.001). (B) NCI-H460:
*significant difference to untreated (siRNA 1: P = 0.2, siRNA 2: P =
0.11), **significantly smaller than 5% (siRNA 3: P = 0.05).
Figure 5 Immunoblot after over-expression of SRD5A1-V5 in
A549 cells and subsequent siRNA transfection. Lysates were
prepared 24 h after siRNA transfection, The percentage signal
intensity compared to lane 7 is given in brackets. The 25 kDa band
corresponds to SRD5A1-V5, the 37 kDa band to GAPDH. Lane 1:
siRNA 1 (31%); lane 2: mm 1 (104%); lane 3: siRNA 2 (22%); lane 4:
mm 2 (87%); lane 5: siRNA 3 (29%); lane 6: mm 3 (107%); lane 7:
plasmid (w/o subsequent siRNA treatment) (100%); lane 8: untreated
(0%).
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matic digestion of DNA in the process of apoptosis.
Polyploidy on the other hand refers to cells with a
hyperdiploid chromosome set. Knock-down of SRD5A1
in A549 or NCI-H460 cells did not alter the percentage
of cells in the different phases of the cell cycle, nor the
number of cells with sub-G1 DNA content or of aneu-
ploid cells. The distribution of cells at 24 h and 48 h
did not vary from the results at 72 h and the data are
therefore not shown.
Apoptosis/necrosis assay
The results of the apoptosis/necrosis assay 72 h after
knock-down of SRD5A1 in A549 or NCI-H460 cells
with 2.5 μl Lipofectamine™ 2000 and 10 pmol siRNA
are displayed in Figure 8. There were no observable dif-
ferences in cell viability between treatment and control
groups in both cancer cell lines. The distribution of cells
a t2 4ha n d4 8hd i dn o tv a r yf r o mt h er e s u l t sa t7 2h
and the data are therefore not shown.
Chemosensitivity assay
Three selective inhibitors of SRD5A1 (ZK 879, ZK 924
and ZK 425 [20], all belonging to the 17-methylene-4-
azasteroids family [19]) and Finasteride, a specific
SRD5A2 inhibitor, were used for chemosensitivity assays
in order to determine whether inhibition of the enzy-
matic activity of SRD5A1 had an effect on cell prolifera-
tion. The results obtained after 120 h of treatment are
presented in Figure 9. Photometrical measurement at 0
h showed equal cell amounts to be present in all treat-
ment and control groups. At 72 h, only Sagopilone (ZK-
EPO)-treated cells showed a decrease in cell viability.
The effect was even more pronounced after 120 h
where a dramatic effect on cell viability was observed.
Conversely, Finasteride and the SRD5A1 inhibitors,
except ZK 425 at the highest concentration used (10
-5
M), had no effect on cell proliferation.
Discussion
Dysregulated expression of discrete sets of genes is fre-
quently observed in many tumor types, including lung
cancer [26-28]. In case an over-expressed gene is cau-
sally involved in cancer growth, its specific blockade
A                                                  A549 
B                                               NCI-H460 
Figure 6 Proliferation assay after siRNA treatment of A549 (A)
and NCI-H460 (B) cells. Experiments were conducted in triplicate
with 10 pmol siRNA and 2.5 μl Lipofectamine™ 2000. No significant
differences were observed between target siRNA-treated and
mismatch siRNA-treated cells in either cell line.
A                                            A549 
B                                        NCI-H460 
Figure 7 Cell cycle analysis 72 h after siRNA treatment of A549
(A) and NCI-H460 (B) cells. Experiments were conducted in
triplicate with 10 pmol siRNA and 2.5 μl Lipofectamine™ 2000. The
cell distribution at 24 h and 48 h did not vary from the results at 72
h and is not shown.
A                                            A549 
B                                       NCI-H460 
Figure 8 Apoptosis/necrosis assay 72 h after siRNA treament
of A549 (A) and NCI-H460 (B) cells. Experiments were conducted
in triplicate with 10 pmol siRNA and 2.5 μl Lipofectamine™ 2000.
The cell distribution at 24 h and 48 h did not vary from the results
at 72 h and is not shown.
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Page 8 of 11may show clinical benefit. This is preferentially achieved
by small molecule or antibody approaches. More
recently, targets with little druggability have been
addressed by RNA interference in order to reduce
expression levels, and first clinical successes have been
reported [29,30].
Elevated levels of SRD5A1 and SRD5A2 have been
reported in prostate cancer and a correlation with the
severity of the disease linked to increased dihydrotestos-
terone levels was documented [14]. SRD5A1 and
SRD5A2 are also consistently over-expressed in breast
cancer, which increases the levels of progesterone meta-
bolites possibly involved in cell proliferation [13].
Indeed, we found SRD5A1 to be markedly elevated in
prostate and breast cancer, and also in several breast
cancer cell lines.
The main finding of the present study is that SRD5A1
is significantly over-expressed in NSCLC. This was
observed in clinical samples originating from two differ-
ent patient populations which were analyzed either by
microarray hybridization or by qRT-PCR. High expres-
sion of SRD5A1 expression was furthermore measured
in the lung cancer cell lines A549 and NCI-H460. A
study was therefore initiated to determine whether
SRD5A1 played a determinant role in lung cancer cell
proliferation. For that, conditions for an efficient
silencing of SRD5A1 expressi o ni nt h e s et w oc e l ll i n e s
via RNA interference were first established. Proliferation
assays and flow cytometry analyses were then con-
ducted. In addition, three SRD5A1 inhibitors were used
for chemosensitivity assays in order to determine if any
anti-proliferative effects could be observed.
Knock-down of SRD5A1 was conducted with the low-
est amount of siRNA still providing an effective reduc-
tion of expression levels [25]. With as little as 10 pmol
siRNA per well of a six-well culture dish, a very good
knock-down to under 20% of SRD5A1 mRNA in all
cases and under 10% of SRD5A1 mRNA in most cases,
when compared to the untreated control, was achieved.
Higher amounts of siRNA (50 and 100 pmol) did not
result in a more effective knock-down. The concentra-
tion of 10 pmol per well was therefore used for all fol-
lowing experiments.
Beside the knock-down of target gene expression,
reduction of the target protein levels needs additionally
to be proven [31]. Despite an effective knock-down of
mRNA, the target protein can persist in the cells, for
example due to a long half-life of the protein. The half-
life of SRD5A1 has been calculated to be 20-30 h in
CHO cells by Russell and Wilson [23]. Due to non-spe-
cific binding, the two commercially available SRD5A1
antibodies could not be used to quantify SRD5A1 pro-
tein levels after siRNA treatment. To determine in an
indirect way whether the three selected siRNAs indeed
decreased the SRD5A1 protein content of the cells,
over-expression of SRD5A1-V5 was conducted together
with siRNA transfection. In A549 cells, a knock-down
was clearly observed after 24 h, the estimated half-life of
SRD5A1-V5 being approximately 12 h, and thus signifi-
cantly shorter than what was observed previously in
CHO cells. Knock-down of over-expressed SRD5A1-V5
at the protein level was also achieved in NCI-H460 lung
cancer cells, the estimated half-life being approximately
20-30 h.
After establishing the optimal conditions for knock-
down of SRD5A1, functional assays were conducted. In
proliferation assays using AlamarBlue, no differences
between target siRNA-treated groups and control
groups were observed. Flow cytometry was performed to
check for more subtle effects. Differences between the
different treatment groups could neither be identified in
cell cycle distribution nor in the apoptosis/necrosis
assay. In the chemosensitivity assays, the only observable
inhibition of proliferation occurred in the group treated
with 10
-5 M ZK425 in A549 cells. As the other concen-
trations did not result in any inhibition of proliferation,
this is likely to represent a non-specific effect linked to
the very high concentration of compound used. In view
of these results, it is unlikely that SRD5A1 contributes
significantly to the proliferation of NSCLC. The
A                                           A549 
B                                      NCI-H460 
Figure 9 Chemosensitivity assay 120 h post-treatment in A549
(A) and NCI-H460 (B) cells. (A) A549: Sagopilone (ZK-EPO)-treated
groups showed significantly less cell viability at each concentration
than the vehicle control (P < 0.001). The ZK 425 group treated at
10
-5 M showed significantly less cell viability than the vehicle
control (P = 0.019). (B) NCI-H460: Sagopilone-treated groups showed
significantly less cell viability at each concentration than the vehicle
control (P < 0.001).
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ing from lung SCC is planned (e.g. in NCI-H520 or
SW-900 cells), since an up-regulation of SRD5A1 has
been observed in tissue samples of SCC as well. Before
that, up-regulation of SRD5A1 needs to be confirmed in
candidate cell lines.
O nt h eo t h e rh a n d ,i tc a n n o tb ee x c l u d e dt h a tt h e
conditions used here did not allow the proper assess-
ment of the role of SRD5A1 in lung cancer. Cultivating
cells in monolayers alters their requirements for growth
factors and stimulatory agents, and gene expression pro-
filing studies show significant differences in comparison
to cells cultivated in three-dimensional conditions (e.g.
spheroid-forming cells), which may better reflect the
situation in the tumor [32,33]. Also, the signals originat-
ing from neighboring stromal cells and from the extra-
cellular matrix influence the pathways that are essential
for tumor cell growth [34,35]. In view of the availability
of selective SRD5A1 inhibitors, one might consider in
vivo testing in nude mice xenografted with human lung
tumor models as a more sophisticated approach to
address these points.
Conclusions
SRD5A1 was found to be up-regulated in NSCLC by
microarray analysis and qRT-PCR. To elucidate whether
SRD5A1 levels influenced the proliferation of NSCLC
cells, knock-down experiments with specific siRNAs
were conducted in A549 and NCI-H460 lung cancer
cells. Despite efficient knock-down, no changes in prolif-
eration, cell cycle distribution or apoptosis/necrosis were
observed. Moreover, blockade of the enzymatic activity
of SRD5A1 with three specific inhibitors did not reduce
proliferation of A549 and NCI-H460 cells. In summary,
SRD5A1 knock-down or inhibition does not affect pro-
liferation of the NSCLC cell lines analyzed.
Additional material
Additional File 1: Location of the siRNA 1-3 binding sites in the
human SRD5A1 cDNA sequence. The position of the siRNA 1-3 binding
sites in the human SRD5A1 sequence is shown. Letters with green
background indicate non-coding regions of the human SRD5A1
sequence (Gene ID: 6715; RefSeq Seq: NM_001047.2), letters with white
background represent the coding sequence. colored letters indicate the
binding site of the specific siRNAs (blue: siRNA 1, green: siRNA 2, red:
siRNA 3).
Additional File 2: Expression construct for CMV-driven expression
of human V5-tagged SRD5A1 protein. A map of the vector used for
expression of human SRD5A1 is shown. The SRD5A1 cDNA was cloned
into the mammalian expression vector pcDNA/V5-His (Invitrogen)
upstream of the V5 tag in order to generate a SRD5A1 fusion protein
with the V5 tag at the C-terminus.
Additional File 3: Structure of 17-methylene-4-azasteroids. The
general chemical structure formula of 17-methylene-4-azasteroids is
shown [20]. For a more detailed structure, also see the review by
Aggarwal et al. [19].
Additional File 4: SRD5A1 expression in normal tissues and in cell
lines. The expression pattern of SRD5A1 was analyzed in a panel of
human tissues (A) and cell lines (B) in the Array Northern database.
Probeset 204675_at which interrogates SRD5A1 on the Affymetrix
HGU133Plus2.0 array is shown. On the x-axis the human tissues and cell
lines are shown sorted by type. The number of replicates analyzed is
indicated. The y-axis depicts arbitrary expression units. In normal tissues,
the highest transcript levels were detected in skin, esophagus, liver, small
intestine, and in neuronal tissue. A relatively weak expression was
observed in normal lung tissue. The cell lines with highest SRD5A1
expression are derived from breast cancer.
Additional File 5: Relative gene expression of SRD5A1 normalized
to cyclophilin 24 h after siRNA-mediated silencing in A549 (A) and
NCI-H460 (B) cells. SRD5A1 silencing experiments were performed in
A549 and NCI-H460 cells in triplicate with 10 pmol siRNA and 5 μl
Lipofectamine™™ 2000. (A) A549: *significant difference to untreated
(mm 1: P = 0.001)¸ **significantly smaller than 5% (siRNA 1: P = 0.001,
siRNA 2: P < 0.001, siRNA 3: P < 0.001). (B) NCI-H460: *significant
difference to untreated (siRNA 1: P = 0.010, siRNA 2: P = 0.004, siRNA 3: P
< 0.001).
Additional File 6: Proliferation assay after siRNA treatment of A549
(A) and NCI-H460 (B) cells. Proliferation experiments were conducted in
triplicate with 10 pmol siRNA and 5 μl Lipofectamine™™ 2000.
Significantly reduced proliferation was observed in all Lipofectamine™™
2000-treated groups (P < 0.001-P = 0.04) in both cell lines.
List of abbreviations
Ct: threshold cycle; FCS, fetal calf serum; NAT: normal adjacent tissue; NSCLC:
non-small cell lung cancer; PCA: principal component analysis; qRT-PCR:
quantitative real-time PCR; SCC: squamous cell carcinoma; SRD5A1: 5-alpha-
reductase type I; SRD5A2: 5-alpha-reductase type II; SRD5A3: 5-alpha-
reductase type III.
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